Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Sold by Easterly Investment Partners LLC

Easterly Investment Partners LLC cut its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 14.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 42,629 shares of the specialty pharmaceutical company’s stock after selling 7,000 shares during the quarter. Easterly Investment Partners LLC owned about 0.13% of Collegium Pharmaceutical worth $1,373,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Gladius Capital Management LP acquired a new stake in Collegium Pharmaceutical during the second quarter worth about $32,000. Principal Securities Inc. acquired a new position in shares of Collegium Pharmaceutical in the fourth quarter worth about $40,000. Assetmark Inc. boosted its stake in shares of Collegium Pharmaceutical by 25.5% during the 4th quarter. Assetmark Inc. now owns 5,445 shares of the specialty pharmaceutical company’s stock worth $168,000 after acquiring an additional 1,108 shares in the last quarter. Sheaff Brock Investment Advisors LLC purchased a new position in Collegium Pharmaceutical during the first quarter worth approximately $204,000. Finally, Gallacher Capital Management LLC acquired a new stake in Collegium Pharmaceutical in the first quarter valued at approximately $223,000.

Collegium Pharmaceutical Trading Up 3.2 %

NASDAQ COLL traded up $1.16 during trading hours on Monday, reaching $37.42. The company had a trading volume of 69,114 shares, compared to its average volume of 461,336. The stock has a market capitalization of $1.22 billion, a P/E ratio of 15.59 and a beta of 0.93. The company has a current ratio of 1.21, a quick ratio of 1.14 and a debt-to-equity ratio of 1.98. The stock has a 50-day moving average of $33.82 and a 200 day moving average of $35.02. Collegium Pharmaceutical, Inc. has a 1-year low of $20.95 and a 1-year high of $40.95.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.22. Collegium Pharmaceutical had a return on equity of 104.98% and a net margin of 16.46%. The company had revenue of $145.28 million for the quarter, compared to analyst estimates of $143.94 million. During the same quarter last year, the company earned $1.13 EPS. Collegium Pharmaceutical’s revenue for the quarter was up 7.2% compared to the same quarter last year. As a group, research analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.73 earnings per share for the current fiscal year.

Insider Buying and Selling at Collegium Pharmaceutical

In other news, CFO Colleen Tupper sold 19,710 shares of the business’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $34.21, for a total transaction of $674,279.10. Following the completion of the sale, the chief financial officer now owns 130,845 shares in the company, valued at approximately $4,476,207.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 3.98% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

COLL has been the subject of several recent analyst reports. HC Wainwright raised shares of Collegium Pharmaceutical from a “neutral” rating to a “buy” rating and set a $47.00 price target for the company in a report on Tuesday, July 30th. Needham & Company LLC reiterated a “hold” rating on shares of Collegium Pharmaceutical in a research report on Friday, August 9th. StockNews.com lowered Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 20th. Truist Financial increased their target price on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $37.00 price objective (down previously from $39.00) on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, Collegium Pharmaceutical has a consensus rating of “Moderate Buy” and an average price target of $42.00.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.